Montelukast Dosage

This dosage information may not include all the information needed to use Montelukast safely and effectively. See additional information for Montelukast.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Allergic Rhinitis

10 mg orally once a day. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one dose daily in the evening.

Usual Adult Dose for Asthma - Maintenance

10 mg orally once a day. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one dose daily in the evening.

Usual Adult Dose for Bronchospasm Prophylaxis

10 mg taken orally at least 2 hours before exercise. Additional doses should not be taken within 24 hours of a previous dose. Patients already taking montelukast daily for another indication (including chronic asthma) should not take an additional dose to prevent exercise induced bronchospasm. All patients should have available for rescue a short-acting beta 2 agonist. Daily administration of montelukast for the chronic treatment of asthma has not been established to prevent acute episodes of exercise induced bronchoconstriction.

Usual Pediatric Dose for Allergic Rhinitis

Montelukast should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one dose daily in the evening.

15 years or older with asthma or allergic rhinitis:
10 mg orally once a day.

6 years to 14 years with asthma or allergic rhinitis:
5 mg chewable tablet orally once a day.

2 years to 5 years with asthma or allergic rhinitis:
4 mg chewable tablet or 4 mg granules orally once a day.

1 year to 2 years with asthma:
4 mg granules orally once a day in the evening.

6 months to 23 months with perennial allergic rhinitis:
4 mg granules orally once a day.

Usual Pediatric Dose for Asthma - Maintenance

Montelukast should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one dose daily in the evening.

15 years or older with asthma or allergic rhinitis:
10 mg orally once a day.

6 years to 14 years with asthma or allergic rhinitis:
5 mg chewable tablet orally once a day.

2 years to 5 years with asthma or allergic rhinitis:
4 mg chewable tablet or 4 mg granules orally once a day.

1 year to 2 years with asthma:
4 mg granules orally once a day in the evening.

6 months to 23 months with perennial allergic rhinitis:
4 mg granules orally once a day.

Usual Pediatric Dose for Bronchospasm Prophylaxis

15 years or older:
10 mg taken orally at least 2 hours before exercise.

6 years to 14 years:
5 mg chewable tablet orally at least 2 hours before exercise.

Additional doses should not be taken within 24 hours of a previous dose. Patients already taking montelukast daily for another indication (including chronic asthma) should not take an additional dose to prevent exercise induced bronchospasm. All patients should have available for rescue a short-acting beta 2 agonist. Daily administration of montelukast for the chronic treatment of asthma has not been established to prevent acute episodes of exercise induced bronchoconstriction.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Limited data have revealed that the half-life may be prolonged in patients with liver disease (average of 7.4 hours). The area under the plasma concentration versus time curve (AUC) is significantly increased in patients with mild to moderate liver disease and clinical evidence of cirrhosis. This may be due to increased bioavailability or decreased drug elimination.

Precautions

Phenylketonuric patients should be informed that the 4 mg and 5 mg chewable tablets contain phenylalanine (a component of aspartame), 0.674 and 0.842 mg per 4 mg and 5 mg chewable tablet, respectively.

Dialysis

Data not available

Severe allergies and anaphylaxis: Learn how epinephrine can save a life. Watch Video

Close
Hide
(web2)